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The ST2 gene is induced in murine ﬁbroblast cells at the start of cell proliferation. Although IL-33 has
been identiﬁed as a ligand for one of the two major gene products of ST2 – namely, the transmembrane
receptor form ST2L – prompting immunological research on inﬂammation, the roles of the ST2 gene
products in cell proliferation remain to be elucidated.
Using a cell proliferation assay system with NIH-3T3 cells, a normal murine ﬁbroblast cell line, we
found that treatment with recombinant ST2 caused an acceleration of cell proliferation, suggesting that
ST2 acts in an autocrine/paracrine fashion. Strikingly, shRNA-induced knockdown of both ST2 gene
products, ST2 and ST2L, reduced cell proliferation. This effect was effectively canceled by the expression
of shRNA-resistant ST2, but not shRNA-resistant ST2L.
The novel enhancement of cell proliferation by ST2 appears to involve positive feedback. Since the
ST2 level is increased in various diseases involving inﬂammation, future investigations into the role of
ST2 gene products in relation to various diseases, including malignancies, may be warranted.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ST2 gene was originally identiﬁed as a gene induced during
the initiation of cell proliferation of quiescent BALB/c-3T3 cells,
and thus was named ST2, short for serum STimulation-2 [1,2].
Since a subsequent investigation revealed that the ST2 gene also
encodes the type I transmembrane protein, ST2L (the Long form of
ST2), which has a sequence very similar to the interleukin 1 re-
ceptor, the focus of the research has shifted to the immunological
aspects [3]. IL-33 was found after a long search for ligand(s) to
ST2L [4], promoting further research into the immune function
(s) of ST2/ST2L in relation to IL-33 signaling [5].
On the other hand, using an ELISA system for the human ST2
protein [6], we found that the ST2 level was increased in serum as
well as other body ﬂuids of patients suffering from various dis-
orders, such as bronchial asthma, systemic lupus erythematosus,
acute eosinophilic pneumonia, idiopathic pulmonary ﬁbrosis,
malignant pleural effusions, and subarachnoid hemorrhage [7–12].
Most surprising was the association between ST2 and myocardialB.V. This is an open access article u
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a).infarction, which has led to the ST2 level being used as a bio-
marker to predict heart failure [13,14].
However, the spectrum of diseases that are accompanied by
high ST2 levels in the serum and body ﬂuids is too broad to be
explained merely by immunological function(s) of the ST2 gene
products. In fact, we found that ST2 suppresses colony formation
of T98G glioblastoma cell line in soft agar [15], and that the ST2 is
directly internalized into dendritic cells [16], and both these
ﬁndings suggest that ST2 has a unique function other than the
sequestration of IL-33 [5].
In the present study, therefore, we investigated the relation
between cell growth regulation and the original ﬁndings for the
ST2 gene. In the course of a previous cell proliferation assay
using NIH-3T3 cells, IL-33 was found to have dual functions with
respect to cell growth – namely, a suppressive effect on the
growth initiation of quiescent cells, and a growth-promoting
effect on cycling cells [17]. However, it remains to be de-
termined whether ST2 and ST2L play any roles in cell growth
regulation. Here we report that ST2 has a growth-promoting
effect in the NIH-3T3 ﬁbroblastic cell line.2. Materials and methods
2.1. Cell culture
The NIH-3T3 cell line, which can be introduced into G0 phase,
was used [17,18]. Each experiment was started by thawing a newnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. RT-PCR analysis of NIH-3T3 cells. (A) RNA extraction and subsequent RT-PCR
were carried out as described in Section 2. The values under h indicate the hours
after growth stimulation. All the products shown correspond to the expected
lengths described in Section 2. (B) Quantitative PCR was carried out as described in
Section 2. mRNA(Ratio) represents the relative amount of mRNA of ST2 or ST2L to
GAPDH.
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(6105 cells per culture dish) in a 10-cm culture dish containing
10 mL of DMEM (D6429; Sigma-Aldrich Co., St. Louis, MO) sup-
plemented with 5% (v/v) heat-inactivated FBS (HyClone; HyClone
Lab. Inc., Logan, UT), 100 U/mL of penicillin (Gibco Life Technolo-
gies Co., Tokyo, Japan), and 100 μg/mL of streptomycin (Gibco),
and cultured at 36.5 °C in a 5% CO2 atmosphere for 5 days. Cell
counting was performed using a SceptorTM handheld automated
cell counter (Millipore Corp., Billerica, MA) throughout the
experiments.
2.2. Cell proliferation assay
The cells cultured for 5 days as described above were washed
twice with PBS, and re-suspended in an appropriate volume of
DMEM plus 5% FBS to 1104 cells/mL. After careful stirring,
0.5 mL of the suspension was added to each well of the 24-well
cell culture plates (Costar 24 Well Clear TC-Treated Multiple Well
Plates #3526; Corning Inc., Corning, NY), resulting in precisely
5103 cells/well (a ca. 1:20 splitting ratio). Blank control wells,
each containing 0.5 mL of the medium without cells, were also
prepared in each plate.
Cell proliferation was measured using a Premix WST-1 cell
proliferation assay system (MK400; TaKaRa Bio, Otsu, Japan). At
the appropriate time, each well was supplemented with 50 μL of
WST-1 solution, and then the plate was carefully shaken 10 times
and kept at 36.5 °C in a 5% CO2 atmosphere. After 2 h, the plate
was again shaken carefully, and then the solution in each well was
mixed well by pipetting. One hundred-microliter samples were
transferred to a 96-well ELISA plate (SUMILON; Sumitomo Bakelite
Co., Ltd., Tokyo, Japan), and processed for measurement of the
absorbance at 450 nm/620 nm using an ImmunoMini NJ-2300
(InterMed Japan Inc., Osaka, Japan). When the absorbance was
expected to be over 2, the assay was terminated at 1 h and the
absorbance was doubled to ensure linearity of the assay.
Three measurements were carried out for each well, and three
independent wells were analyzed for a particular time point. Every
experiment was repeated at least 3 times beginning with thawing
of the frozen cells. The excellent correspondence between the
WST-1 assay and cell counting method has already been conﬁrmed
in our previous report [17].
2.3. RNA extraction
Total RNA was extracted using TRIzol Reagent (Life Technolo-
gies, Carlsbad, CA). The cells were cultured and treated with a 1:20
splitting ratio in the same manner as in the cell proliferation assay,
with the exception that 10-cm-diameter cell culture dishes were
used instead of 24-well plates. Since the concentration of RNA in
the extract was expected to be low due to the sparseness of the
culture, RNA grade glycogen (#R0551; Thermo Scientiﬁc) was used
as a carrier in the precipitation process using isopropanol. The ﬁ-
nal concentration of RNA dissolved in H2O was measured with a
NanoDrop 2000c spectrophotometer (Thermo Scientiﬁc).
2.4. Reverse transcription and PCR (RT-PCR)
One microgram of the total RNA was denatured at 70 °C for
10 min and immediately chilled on ice. The ﬁrst-strand DNA was
synthesized at 37 °C for 1 h in a total volume of 20 μL using oligo
(dT12–18) primer (Sigma-Aldrich) and M-MLV Reverse Tran-
scriptase (Life Technologies) as described previously [19]. PCR
ampliﬁcation was carried out with synthesized cDNA derived from
0.05 μg of total RNA in a ﬁnal volume of 20 μL using an Advantage
2 PCR Kit (Clontech, Mountain View, CA) [20]. The standard PCR
conditions were 95 °C for 10 min, followed by 30 cycles of 94 °C for1 min, 55 °C for 1 min, and 72 °C for 2 min, and a ﬁnal treatment at
72 °C for 10 min. The nucleotide sequences of the forward primers
were as follows: for ST2 and ST2L (derived from a common region
of mouse ST2 and ST2L in the exon 6) [2,3,21], 5′-CAAATCCTCCA-
TACAACCAC-3′; and for GAPDH, 5′-CCATCACCATCTTCCAGGAG-3′.
The nucleotide sequences of the reverse primers were as follows:
for ST2 (in exon 8), 5′-TCAAGCAATGTGTGAGGGAC-3′; for ST2L (in
exon 9), 5′-AGGTGTCACTATATCTCTCC-3′; and for GAPDH, 5′-CCT-
GCTTCACCACCTTCTTG-3′.
All primer sets are on different exons, thereby avoiding the
effect of contamination of genomic DNA in RNA preparations, if
any. The expected lengths of the PCR products were 353 bp for
ST2, 458 bp for ST2L, and 576 bp for GAPDH, respectively.
Five microliters of PCR products were developed by electro-
phoresis on 1.2% agarose gels, and the gels were stained with
ethidium bromide.2.5. Quantitative PCR analysis
Quantitative PCR by using KAPA SYBR Fast qPCR kit (KAPA
Biosystems, Wilmington, MA, USA) was performed in a LightCycler
96 (Roche Diagnostics, Indianapolis, IN, USA) with PCR cycles set at
95 °C for 10 s, 55 °C for 10 s, and 72 °C for 10 s. The nucleotide
sequences of the forward primers used for the quantitative PCR
were as follows: for ST2 and ST2L 5′-CAAGAAGAGGAAG-
GTCGAAATG-3′; and for GAPDH 5′-ATTCCACCCATGGCAAATTC-3′.
The nucleotide sequences of the reverse primers were as follows:
for ST2, 5′-ATGTGTGAGGGACACTCCTTAC-3′; for ST2L, 5′-AGCAA-
CCTCAATCCAGAACAC-3′; and for GAPDH, 5′-GATGGGATTTCCATT-
GATGACA-3′.
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Fig. 2. Expression of ST2 and ST2L in the derivative cells of NIH-3T3 cells. (A) Quantitative PCR analysis was performed as in Fig. 1B. (B) FLAG-tagged ST2 and ST2L proteins in
conditioned media (CM) and whole cell lysate (WCL) from the infected NIH-3T3 cells were detected by immunoblotting with M2 antibody.
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Human embryonic kidney 293T cells (HEK293T) were trans-
fected with helper retrovirus plasmids including pE-Eco and pGP
(TAKARA, Japan) together with MSCV-ires-PuroR (murine stem cell
virus (MSCV)-internal ribosome entry site (IRES)-puromycin
N-acetyltransferase vectors) encoding ST2-FLAG or ST2L-FLAG
proteins tagged with FLAG on their C-termini. The viruses were
harvested from culture supernatants and stored on ice. Ex-
ponentially growing cells (1105 cells per 60-mm-diameter cell
culture dish) were infected with virus-containing supernatant in
complete medium containing 1.0 μg/mL Polybrene (Sigma-Aldrich,
St. Louis, MO). The infection efﬁciencies were conﬁrmed by pur-
omycin selection. The resulting transfected cells were designated
as NIH-ST2 and NIH-ST2L, respectively. The cells transfected with
an empty virus as a control were designated NIH-MSCV.
2.7. Immunoblotting
The infected cells were lysed with RIPA buffer (10 mM sodium
phosphate, pH 7.2, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% so-
dium deoxycholate, 0.2 U/ml aprotinin, and phosphatase in-
hibitors). To detect secreted ST2, the culture supernatant was also
collected. These samples were electrophoretically separated by
SDS-PAGE and transferred to polyvinylidene diﬂuoride mem-
branes (Merck Millipore). Proteins were detected with M2
monoclonal antibody against Flag tag (M2; Sigma-Aldrich).2.8. Puriﬁcation of recombinant ST2 protein
To purify the recombinant ST2 protein, the culture supernatant
of NIH-ST2 cells infected with the retrovirus harboring ST2-FLAG
was collected. Similarly, the culture supernatant of control NIH-
MSCV cells was also harvested to prepare a control fraction. These
culture supernatants were mixed with 50 μL of M2-agarose (Sig-
ma-Aldrich) at 4 °C for 90 min. The precipitated complexes were
washed with PBS ﬁve times, and then the fraction including ST2-
FLAG was eluted by the addition of PBS including 400 μg/mL of
FLAG peptide (Sigma-Aldrich). The purity and approximate protein
amount of puriﬁed ST2-FLAG were evaluated by Coomassie Bril-
liant Blue (R-250) staining with bovine serum albumin as a stan-
dard protein for the calibration after SDS-PAGE.
2.9. RNA interference
Annealed oligonucleotides coding shRNA for both murine ST2 and
ST2L were inserted into a pSUPER-retro-puro retroviral plasmid
(Oligoengine, Seattle, WA). The retroviruses were prepared by trans-
fection into HEK293T cells, and utilized for the infection into NIH-3T3
cells by the same method as used for MSCV retroviral plasmids. The
efﬁciency of knockdown was evaluated by RT-PCR and immunoblot
analysis with an M2 antibody. The sequences of oligonucleotides used
for constructing the shRNA retroviral vectors for KD (knockdown)
2 cells were 5′-GATCCCCaaggataactggtgtgacaTTCAAGAGAtgtcacacc-
agttatccttTTTTTA-3′ and 5′-AGCTTAAAAAaaggataactggtgtgacaTCTCTT-
GAAtgtcacaccagttatccttGGG-3′ (underlined sequences correspond to
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Fig. 3. Cell proliferation assay. (A) A cell proliferation assay was carried out for NIH-ST2 cells (solid line) and control NIH-MSCV cells (broken line) as described in Section 2.
Error bars indicate the S.D. The asterisks denote P values o0.01. (B) A cell proliferation assay was carried out for NIH-ST2L cells (solid line) and control NIH-MSCV cells
(broken line) as in Panel A. (C) The culture supernatants of NIH-ST2 cells (solid line) and NIH-MSCV cells (broken line) were collected after 3 days, and then freshly seeded
NIH-3T3 cells were cultured with the conditioned medium. A cell proliferation assay was carried out as in Panel A. (D) The recombinant soluble ST2 was puriﬁed as described
in Section 2, and a cell proliferation assay was carried out as in Panel A. The concentration of soluble ST2 was 500 ng/mL. Error bars indicate the S.D. The asterisks denote P
values o0.01.
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sequences for KD1 and KD3 cells were acacaatggaagtggaaat (677–
695) and agaggaaggtcgaaatgaa (819–837), respectively. As control, an
shRNA construct against ﬁreﬂy luciferase was used in KD0 cells. To
express shRNA-resistant ST2 and ST2L in KD2-ST2/ST2L-knockdown
cells, ﬁve nucleotides in the shRNA target sequence were mutated to
avoid RNAi targeting (Fig. 4B). The mutations did not alter the amino
acid sequences of ST2 and ST2L.2.10. Cell cycle analysis
For analysis of synchronized cells, NIH-3T3 cells were arrested
at G0 phase by subjecting them to contact inhibition during culture
to conﬂuence. The synchronized cells were released into the cell
cycle by splitting the cells onto new dishes. At the indicated per-
iods, cells were ﬁxed and suspended with the lysis buffer including
propidium iodide and RNase A for ﬂow cytometry. Cell cycle data
were collected using LSRFortessa (Becton Dickinson, Franklin
Lakes, NJ) and analyzed with FlowJo software version 10.0.8 (Tree
Star Inc., Ashland, OR).2.11. Trypan blue exclusion assay
NIH-3T3 cells were arrested at G0 phase by subjecting them to
contact inhibition during culture to conﬂuence. The synchronized
cells were released into the cell cycle by splitting the cells onto new
dishes. After 2 and 4 days, cells were harvested and stained with
trypan blue. Viable cells, which excluded trypan blue dye, were
counted in triplicate with a Countess (Invitrogen, Carlsbad, CA).
2.12. Statistical analysis
The results were recorded as the mean7S.D. Student’s t-test
was performed to analyze the differences in absorbance at 450 nm/
620 nm, which represented cell growth. A P-value of less than 0.01
was considered statistically signiﬁcant in all experiments.3. Results
The NIH-3T3 cells showed density inhibition and subsequent
ST2 gene induction by growth stimulation as reported previously
for BALB/c-3T3 cells (Fig. 1) [1,2,18]. To determine whether
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3T3 cell proliferation, we constructed NIH-ST2, NIH-ST2L, and
control NIH-MSCV cells as described in Section 2. The continuous
overexpression of ST2 and ST2L mRNAs in NIH-ST2 and NIH-ST2L
cells, respectively, was conﬁrmed (Fig. 2A). The corresponding
protein products were detected in the cell lysates (Fig. 2B). Im-
portantly, ST2 protein was detected in the culture medium of NIH-
ST2 cells, but not in those of NIH-MSCV and NIH-ST2L cells.
The cell proliferation assay was performed according to the
previous report [17]. Continuous expression of ST2 enhanced cell
growth (Fig. 3A). However, the overexpression of ST2L had no
apparent effect on cell proliferation (Fig. 3B). We next examined
the effect of conditioned media from NIH-ST2 cells on the pro-
liferation of NIH-3T3 cells. NIH-3T3 cells treated with the medium
containing ST2 showed a signiﬁcantly higher level of growth than
those treated with the conditioned medium from NIH-MSCV cells
(Fig. 3C). Moreover, the addition of puriﬁed ST2 to the culture
medium also enhanced cell proliferation (Fig. 3D).
One difﬁcult to interpret result of this study was that the en-
dogenous ST2 gene was induced by growth stimulation, and ST2
protein was excreted even in the control NIH-3T3 cells after the
initiation of cell proliferation (Fig. 1) [2]. Therefore, the qualitative
difference between NIH-MSCV and NIH-ST2 cells was that ST2 wasexpressed only in the density-inhibited quiescent state (Fig. 2A).
To overcome the inherent limitations of a mutant over-
expression study, we next performed a knockdown experiment.
According to the method used to explore candidate sequences,
3 possible sequences for short hairpin construction, located in the
common region between ST2 and ST2L, were proposed, and the
vectors and resulting transformed cells were named KD1, 2, and 3,
respectively, as described in Section 2. Unfortunately, no appro-
priate sequence speciﬁc to ST2 or ST2L was proposed.
Although the knockdown process did not work in KD1 cells
(data not shown), we were able to conﬁrm that both the ST2 and
ST2L expressions were suppressed in KD2 and KD3 cells (Fig. 4A).
A cell proliferation assay revealed that these suppression were
much higher in the KD2 and KD3 cells than in the control KD0
cells, suggesting that the ST2 gene expression promoted growth of
NIH-3T3 cells (Fig. 5A,B).
Because the expressions of both ST2 and ST2L were reduced in
KD2 and KD3 cells, the next question was which was responsible
for the observed enhancement of cell growth. To address this, we
attempted to express the shRNA-resistant ST2 or ST2L in cells in
which the ST2 gene products were reduced, and then observed the
effects on cell proliferation.
As shown in Fig. 4B, we constructed vectors carrying mutated
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target sequence was exchanged in order to avoid degradation of
mRNA, while still encoding the same protein product from native
mRNA. Then the additional infection of retroviruses encoding
shRNA-resistant ST2 and ST2L was performed, and the resultant
cells were named KD2RST2 and KD2RST2L, respectively. Indeed,
the expressions of the mRNA and protein product for ST2 were
recovered in KD2RST2 cells, and the expressions of the mRNA and
protein product for ST2L were recovered in KD2RST2L cells, while
both were reduced in KD2 cells (Fig. 4C,D).
The cell growth was recovered to a level similar to that in the
control when the expression of the ST2 protein was restored by
supplementation with the ST2-producing vector (Fig. 5C). On the
other hand, supplementation with the ST2L-producing vector had
no apparent effect on the cell growth (Fig. 5D). Taken together, these
results showed that ST2 promoted the growth of NIH-3T3 cells.
To clarify the effect of ST2 protein on cell cycle, we next com-
pared the cell cycle progression between NIH-3T3 cells and re-
combinant ST2-treated NIH-3T3 cells. As shown in Fig. 6A, the
treatment with the ST2 protein caused a slight increase of the
population in G2/M phase after 16 h, however this alteration was
hard to use for the explanation of the mechanism how the ST2
protein accelerates the cell proliferation. In addition, we treated
the cells with the ST2 protein in 12 h after splitting the cells, and
further 48 h later, we analyzed their cell cycle. As shown in Fig. 6B,
ST2 still increased the population in G2/M phase. In 12 h after
releasing from G0 phase, cells were still in late G1 phase (Fig. 6A).
These observations suggest that ST2 accelerates the cellproliferation through modifying cell cycle steps such as S and G2/
M phase but not early G1 phase, although the detailed mechanism
is not clear yet. The addition of the ST2 protein did not affect cell
survival (Fig. 6C).4. Discussion
The key point in the present experimental design was the in-
troduction of ﬁbroblastic cells into a quiescent state in which en-
dogenous ST2 gene expression was scarcely detected (see Fig. 1
and [2]), before starting the cell proliferation assay. As described in
the Introduction, the ST2 gene was originally identiﬁed as a gene
induced in the course of the initiation of cell proliferation of
quiescent BALB/c-3T3 cells [1,2]. In our present experiments, we
similarly observed the serum-induced expression of ST2 gene
products in NIH-3T3 cells. NIH-3T3 cells are the most useful cell
line for analysis of the cell cycle, because they can be easily in-
duced into G0 phase by cell density growth inhibition [17,18]. Since
the ST2 gene is continuously expressed throughout the cell growth
cycle [2], it is difﬁcult to determine the effect of adding ST2 in
cycling cells. Indeed, no remarkable growth-enhancing effects of
ST2 were detected in our preliminary experiments using con-
tinuously growing NIH-3T3 cells (data not shown).
Recently, we found that IL-33 had a dual function in the cell
proliferation of NIH-3T3 cells [17]. In addition, we previously re-
ported that ST2 inhibited the IL-33–ST2L signaling pathway by
capturing IL-33 in media [5], and thus the relationship between
Fig. 6. Effect of soluble ST2 on cell cycle progression and cell viability in NIH-3T3 cells. (A) NIH-3T3 cells were released from G0 phase into culture medium with (þ) or
without () 500 ng/mL of recombinant soluble ST2. The cells were harvested at the indicated time points for cell cycle analysis by ﬂow cytometer. (B) NIH-3T3 cells were
released from G0 phase for 12 h before the medium were replaced by culture medium with (þ) or without () 500 ng/mL of recombinant soluble ST2 for 48 h. After this
period, the cells were harvested for cell cycle analysis by ﬂow cytometer. (C) NIH-3T3 cells were released from G0 phase into culture medium with (þ) or without (–)
500 ng/mL of recombinant soluble ST2. After 2 and 4 days, cell viability was assessed by the trypan blue exclusion assay. Error bars, S.D. (n¼3).
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lation in a batch of preliminary experiments, but we found no
positive or negative effect of IL-33 on the enhancement of cell
proliferation of NIH-3T3 by the addition of ST2. Pre-treatment
with IL-33 also did not inﬂuence the ST2-induced promotion of
cell proliferation (data not shown) [17]. At present, it appears that
ST2 itself may be responsible for the growth enhancement of NIH-
3T3 cells, via an as-yet-unknown cell surface receptor for ST2 or
via direct internalization as reported previously [16]. Indeed, the
unexpectedly remarkable effect of shRNA-resistant ST2 (Fig. 5C)
suggested that the ﬁnal target of the ST2 action may be inside the
cells.
Knockdown strategy for ST2L has essential limitations. In part,
this is because a major function of ST2L is receptor activity in
collaboration with IL-1RAcP to transduce IL-33 signals into the
cellular interior. Generally, a small amount of receptor molecule on
the cell surface is sufﬁcient for signal transmission, as reported
previously for IL-1 receptors [22,23]. The ST2L molecules remain-
ing after the knockdown procedure might have been adequate for
signal transduction, with the result that no obvious effects of ST2L
supplementation were detected. At least, we showed that over-
expression of ST2L had no effect on the growth of NIH-3T3 cells
(Fig. 3B). In addition, ST2-deﬁcient mice have been shown to be
defective in the development of Th2-like cytokine responses, but
are not lethal in terms of ontogenesis [24]. Since both ST2 and
ST2L are defective in ST2-deﬁcient mice, some redundancy might
be at play, which would suggest that ST2 and/or ST2L are not in-
dispensable for cell growth itself.Since the ST2 gene is induced in the course of initiation of cell
proliferation, from G0 to G1/S in an all-or-none fashion [2], the
possibility of a positive feedback system in cell growth regulation
is of great interest and would be worth investigating in relation to
the etiology and prognosis of various diseases. Indeed, as for ma-
lignancies, there are several reports suggesting positive or nega-
tive effect of IL-33–ST2/ST2L axis on cell growth, cell migration,
and anchorage-independent cell growth [15,25–27]. So far, we
have no suitable explanation for this discrepancy about the dif-
ferences of effect that ST2 exhibits against tumor growth. How-
ever, our current research is the ﬁrst case, which shows the
function of ST2 protein stimulating cell growth of un-transformed
ﬁbroblast. Our simple experimental system presented here may be
helpful to enhance such investigations.Author disclosure statement
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